Subscribe to Newsletter

Drug Discovery

Discovery & Development Drug Discovery

A New Model of Drug Discovery

| Jamie Irvine | 2 min read

How multi-omics and AI-driven target identification can drive the future of personalized medicine

Discovery & Development Drug Delivery

One Vaccine to Rule Them All

| Jamie Irvine | 2 min read

A superbug vaccine could protect patients against multiple healthcare-associated infections at once

Discovery & Development Drug Discovery

Minds, Interrupted

| Ashlea Segal, Alex Fornito | 2 min read

Researchers develop a new approach to mapping the individual heterogeneity of brain changes in mental disorders

Discovery & Development Drug Discovery

A Chip Off the New Block

| Tomasz Kostrzewski | 3 min read

In vivo animal models have brought much to the science behind the drug development industry, but how far behind are organ-on-a-chip models?

Discovery & Development Drug Discovery

Opiate Dreams and Nightmares

| Jamie Irvine | 3 min read

Experimental insomnia drug shows promise in alleviating opioid withdrawal symptoms and opioid-seeking behavior

Discovery & Development Drug Discovery

Making Miracles

| 6 min read

After serving as Head of Research Development at Trinity College Dublin, Fiona Killard-Lynch became Director of Research and Innovation at NIBRT

Discovery & Development Drug Discovery

The Clinical Cosmos: Exploring Medicine's New Frontier

| Deepika Khedekar | 7 min read

Deepika Khedekar explores the unique environment of space and its implications for clinical research.

Business & Regulation Digital Technologies

Can AI Tackle Drug Shortages?

| Jo Varshney | 4 min read

Exploring the role of AI in helping bring more medicines to market.

Discovery & Development Drug Discovery

Alzheimer’s Disease: The Winds of Progress

| Jamie Irvine | 10 min read

Howard Fillit shares his views on the historical research lag, the slim successes so far, and the target pathways that offer most hope

Discovery & Development Drug Discovery

QTOF: Quick Off the Mark for Oligonucleotide Analysis

| Timo Schierling, Julia Schneider, Stephan Seiffert, Christian Albers | 4 min read

Experts from Axolabs GmbH and Bruker Daltonics explain the benefits behind mass spectrometry for oligonucleotides in drug discovery

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register